Cited by

• Relationship between serum apolipoprotein B and risk of all-cause and cardiovascular disease mortality in individuals with hypertension: a prospective cohort study.

  Huang Y, Chen S, Pan H, Yang S, Cheng W. Huang Y, et al. BMC Cardiovasc Disord. 2024 May 24;24(1):273. doi: 10.1186/s12872-024-03949-1. BMC Cardiovasc Disord. 2024. PMID: 38789961 Free PMC article.
• Genetic and molecular architecture of familial hypercholesterolemia.

  Abifadel M, Boileau C. Abifadel M, et al. J Intern Med. 2023 Feb;293(2):144-165. doi: 10.1111/joim.13577. Epub 2022 Oct 17. J Intern Med. 2023. PMID: 36196022 Free PMC article. Review.
• A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients.

  Li F, Ye P, Hao Y, Du J, Zhang H, Wang Z, Wang X, Zeng H, Ma Y, Lin J. Li F, et al. Atheroscler Plus. 2022 May 18;49:12-19. doi: 10.1016/j.athplu.2022.05.002. eCollection 2022 Aug. Atheroscler Plus. 2022. PMID: 36644203 Free PMC article.
• Analysis of Rare Variants in Genes Related to Lipid Metabolism in Patients with Familial Hypercholesterolemia in Western Siberia (Russia).

  Shakhtshneider E, Ivanoshchuk D, Timoshchenko O, Orlov P, Semaev S, Valeev E, Goonko A, Ladygina N, Voevoda M. Shakhtshneider E, et al. J Pers Med. 2021 Nov 19;11(11):1232. doi: 10.3390/jpm11111232. J Pers Med. 2021. PMID: 34834584 Free PMC article.
• Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota-Immunity Axis in the New Diagnostic and Prognostic Frontiers.

  Piccioni A, Niccolai E, Rozzi G, Spaziani G, Zanza C, Candelli M, Covino M, Gasbarrini A, Franceschi F, Amedei A. Piccioni A, et al. Pathogens. 2023 Apr 21;12(4):627. doi: 10.3390/pathogens12040627. Pathogens. 2023. PMID: 37111513 Free PMC article. Review.